Evidence map›Paper›PMID 42718814›Full record

ArticleFrontiers in cellular and infection microbiology2026

α-Terpineol reverses

Yujuan Li, Yi Yang, Ting Zhou, Jing Zhou, Jie Hu, Shuangshuang Liang, Zhenhua Xie, Qing Cheng, Yachao Jiang, Chao Jiang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yujuan LiCollege of Basic Medicine, Xiangnan University, Chenzhou, China.
Yi YangCollege of Basic Medicine, Xiangnan University, Chenzhou, China.
Ting ZhouCollege of Clinical, Xiangnan University, Chenzhou, China.
Jing ZhouCollege of Clinical, Xiangnan University, Chenzhou, China.
Jie HuCollege of Basic Medicine, Xiangnan University, Chenzhou, China.
Shuangshuang LiangCollege of Clinical, Xiangnan University, Chenzhou, China.
Zhenhua XieCollege of Basic Medicine, Xiangnan University, Chenzhou, China.
Qing ChengCollege of Basic Medicine, Xiangnan University, Chenzhou, China.
Yachao JiangCollege of Pharmacy, Xiangnan University, Chenzhou, China.
Chao JiangCollege of Basic Medicine, Xiangnan University, Chenzhou, China.
Qing LiuHunan Provincial Key Laboratory of Gut Microbiota and Chronic Disease Intervention, Chenzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amid the growing antibiotic resistance crisis, colistin remains a last-line therapeutic option for multidrug-resistant (MDR) Gram-negative bacterial infections. However, the emergence and rapid dissemination of plasmid-mediated colistin resistance gene (

Indexed as

Anti-Bacterial AgentsColistinDrug Resistance, Multiple, BacterialEscherichia coliEscherichia coli ProteinsMonoterpenesAnimalsCyclohexane MonoterpenesDisease Models, AnimalDrug SynergismEscherichia coli InfectionsMembrane FluidityMiceMicrobial Sensitivity Testsalpha-terpineolAnti-Bacterial AgentsColistinCyclohexane MonoterpenesEscherichia coli ProteinsMonoterpenesantibiotic adjuvantcolistinEscherichia coliMCRmultidrug-resistantα-terpineol

Identifiers

PMID42718814
PMCPMC13553474

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.